SOURCE: Goldman Small Cap Research, Inc.

November 06, 2013 09:30 ET

Unlike Other Biotechs, It Is Full Steam Ahead for Nuvilex

BALTIMORE, MD--(Marketwired - Nov 6, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that in a year where there have been quite a few misfires in the small biotech world, Nuvilex, Inc. (OTCQB: NVLX) is a shining star. It seems that not a day goes by when a small to medium sized biotech stock does not take it on the chin. To be sure, the biotechnology industry is characterized as a marathon rather than a sprint. As a result, nearly all companies succumb to fits and starts along the development process. It is practically a routine event considering it can happen with some frequency.

In Nuvilex's case, one would be hard pressed to argue against the series of positive developments that have occurred, which have launched the Company's stock to a settling point in the teens. And, with more good news in the offing, the stock appears poised to hit new highs. Already this year the Company has acquired rights to groundbreaking live-cell encapsulation technology to treat cancer that has completed clinical trials, raised $1.25 million at a premium to the market with limited dilution, reduced debt by more than $2 million and has made material progress in its plan to launch advanced clinical trials. 

Earlier this week, Nuvilex announced that cloning of the cancer-drug-activating cells required for Nuvilex's future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Following receipt by Inno Biologics of four vials of frozen cells capable of converting the well-known anticancer prodrug ifosfamide into its active cancer-killing form, one of the vials was thawed and the cells grown in culture. The cells, which were previously grown by ViruSure in Vienna, were successfully thawed, and approximately 97% of the cells were found to be viable. The best clones will be propagated to obtain large numbers of cells required for the late-phase clinical trials of Nuvilex.

With each small step forward, the risk in these shares decreases and the value of the stock increases. However, when major steps such as the closing of the previously announced diabetes acquisition occurs, incremental moves higher should be replaced by major reductions in risk and an associated substantial increase in value, reflecting the new, large opportunity.

This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.

Contact Information